PCOS, A Long Misunderstood Condition, Got a New Name This Week

Reported by Vogue.

Something quietly significant happened in medicine this week: polycystic ovary syndrome, the hormonal disorder affecting more than 170 million women globally, got a new name. A global consortium of doctors and researchers announced the condition will now be called PMOS — polyendocrine metabolic ovarian syndrome — a renaming designed to finally reflect what the disorder actually does to the body. "The term polycystic ovary syndrome has long been recognized as inaccurate and potentially harmful," the initiative's team wrote, noting the old name fixated on a single organ while the reality is far more systemic. It's a long-overdue correction for a condition that, according to Vogue, leaves nearly 70% of its estimated cases undiagnosed, per WHO data.

The name change matters because the condition itself has always been bigger than its label. PMOS is a hormonal and metabolic disorder — yes, it disrupts ovulation and can cause irregular periods, excess androgen symptoms like acne and unwanted hair growth, and fertility challenges, but it's equally entangled with insulin resistance, cardiovascular risk, and dermatologic symptoms. New York reproductive endocrinologist Dr. Margaret Natchigall describes it as a broad diagnosis with wildly varied presentations. And research from Dr. Jia Zhu, a pediatric endocrinologist at Boston Children's Hospital, suggests genetic risk markers can show up in children before they even reach reproductive age — meaning this isn't just a "woman's problem" that starts at puberty.

The Diagnosis Gap Is the Real Crisis

Getting diagnosed is its own obstacle course. There's no single definitive test — clinicians typically rely on the Rotterdam criteria, which requires two of three factors: irregular ovulation, elevated androgen signs, or polycystic-appearing ovaries on ultrasound. But because PMOS is a diagnosis of exclusion — thyroid, pituitary, and adrenal disorders must be ruled out first — the process drags. Dr. Lora Shahine, a Seattle-based OB-GYN and reproductive endocrinologist, warns it can also swing toward overdiagnosis if ultrasound alone is used. Meanwhile, Dr. Thais Aliabadi, L.A.-based OB-GYN and co-founder of Ovii Health, puts the failure plainly: symptoms get dismissed as stress, split across specialties, or chalked up to "normal hormones," leaving women without real answers for years.

The mental health dimension is arguably the most underreported part of this story. Dr. Sarah Oreck, reproductive psychiatrist and founder of Mavida Health, frames PMOS as a neurometabolic condition — insulin resistance disrupts neurotransmitter function, chronic inflammation affects mood regulation, elevated androgens destabilize emotional wellbeing. Women with PMOS are two to three times more likely to develop anxiety and depression, and 1.5 to 2 times more likely to develop PMDD. The Endocrine Society now recommends routine mental health screening as standard care. "Addressing mental health isn't optional or secondary in PMOS care; it's central to it," Oreck says — and for women who've spent years being told their labs are fine, that validation alone is something.

A renamed condition won't fix the diagnostic gap, the underfunded research, or the years women have lost to medical dismissal — but it's a start that finally puts the full picture in the name itself.

Read the original at Vogue.